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Available online 26 June 2016Tyrosine sulfation is a post-translationalmodiﬁcation that facilitates protein-protein interaction. Two sulfated ty-
rosines (Tys173 and Tys177) were recently identiﬁed within the second variable (V2) loop of the major HIV-1
envelope glycoprotein, gp120, and shown to contribute to stabilizing the intramolecular interaction between
V2 and the third variable (V3) loop. Here, we report that tyrosine-sulfated peptides derived from V2 act as struc-
tural and functional mimics of the CCR5 N-terminus and potently block HIV-1 infection. Nuclear magnetic and
surface plasmon resonance analyses indicate that a tyrosine-sulfated V2 peptide (pV2α-Tys) adopts a CCR5-
like helical conformation and directly interacts with gp120 in a CD4-dependent fashion, competing with a
CCR5 N-terminal peptide. Sulfated V2 mimics, but not their non-sulfated counterparts, inhibit HIV-1 entry and
fusion by preventing coreceptor utilization, with the highly conserved C-terminal sulfotyrosine, Tys177, playing
a dominant role. Unlike CCR5 N-terminal peptides, V2 mimics inhibit a broad range of HIV-1 strains irrespective
of their coreceptor tropism, highlighting the overall structural conservation of the coreceptor-binding site in
gp120. These results document the use of receptor mimicry by a retrovirus to occlude a key neutralization target
site and provide leads for the design of therapeutic strategies against HIV-1.
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Progressive reﬁnement of the molecular anatomy of the native HIV-1
envelope spike, which represents the sole target of neutralizing antibod-
ies, is accruing critical information for the rational design of effective in-
hibitors and vaccine immunogens (Burton et al., 2012; Mascola and
Haynes, 2013; Wyatt and Sodroski, 1998). The envelope spike displayed
on the surface of infectious virions is a homotrimer of gp120:gp41hetero-
dimers (Wyatt and Sodroski, 1998). Due to inherent difﬁculties in crystal-
lizing the native envelope trimer, most high-resolution structures were
initially obtained with monomeric gp120 stabilized in complex with sol-
uble CD4 (sCD4) and/or speciﬁc monoclonal antibodies (mAb) (Chen et
al., 2009; Huang et al., 2005, 2007; Kwon et al., 2012; Kwong et al.,
1998, 2000; Pancera et al., 2010). Recently, important progress has beens Hopkins School of Medicine,
le Street, Burlington, VT 05401.
ss article under the CC BY-NC-ND licmade with the design of soluble, cleaved, disulﬁde bridge-stabilized
gp140 trimers (SOSIP.664), which display several features of the pre-fu-
sion envelope spike (Sanders et al., 2013), although the stabilizing muta-
tions were shown to abrogate fusion competence and to induce some
alterations of the antigenic proﬁle (Alsahaﬁ et al., 2015). The structure
of several SOSIP.664 trimers has been resolved by crystallization or
high-resolution cryogenic electronmicroscopy (cryoEM), providing valu-
able information on the pre-fusion conformation of the envelope trimer
(Bartesaghi et al., 2013; Julien et al., 2013; Kwon et al., 2015; Garces et
al., 2015; Lyumkis et al., 2013; Pancera et al., 2014; Stewart-Jones et al.,
2016). Additional insights have come with the progressive increase in
cryoEM imaging resolution of bona ﬁdenative trimers expressed on virion
or cellular surface membranes (Hu et al., 2011; Lee et al., 2016; Liu et al.,
2008; White et al., 2010; Wu et al., 2010). Despite these remarkable ad-
vancements, however, several aspects of the structure-function relation-
ships in the HIV-1 envelope spike remain to be deﬁned, which may be
critical for the design of effective inhibitors targeting functional elements
of the HIV-1 envelope spike.
We recently reported the identiﬁcation of two sulfated tyrosines
(Tys173 and Tys177) within the second variable (V2) domain of HIV-ense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tion sensitivity and, thereby, may facilitate immune evasion (Cimbro
et al., 2014), an art mastered by HIV-1 to limit the immune system abil-
ity to recognize conserved neutralization epitopes (Chen et al., 2009;
Kwong et al., 2002; Liu et al., 2011; Pancera et al., 2010; Pinter et al.,
2004). Tyrosine sulfation was documented in gp120 from multiple
HIV-1 strains grown in primary human CD4+ T cells, including primary
isolates minimally passaged ex vivo, thus corroborating its physiological
relevance. Remarkably, the V2 sulfotyrosines are identically spaced as
two critical sulfated tyrosines within the N-terminal domain of the
CCR5 coreceptor, which were shown to bolster the interaction of CCR5
with the base of the gp120 third variable (V3) domain, facilitating
HIV-1 entry (Farzan et al., 1999; Huang et al., 2007). In line with these
observations, tyrosine-sulfated peptides derived from the CCR5 N-ter-
minus were shown to speciﬁcally inhibit infection by CCR5-tropic
HIV-1 isolates (Cormier et al., 2000; Cormier et al., 2001; Farzan et al.,
2000). Likewise, a chimeric molecule encompassing a tyrosine-sulfated
peptide inserted at the C-terminus of CD4-Ig was recently reported to
possess potent antiviral activity against a broad range of HIV-1 isolates
(Gardner et al., 2015).
Based on these observations, we hypothesized that the sulfated re-
gion of the V2 loop could functionally mimic the sulfated N-terminus
of CCR5 and establish an intramolecular interaction with the
coreceptor-binding site at the base of the V3 loop. In the unliganded en-
velope, this interaction could serve as a structural constraint to stabilize
the closed pre-fusion conformation of the trimer. Consistent with this
hypothesis, recent crystallographic structures obtained with soluble
SOSIP trimers show the V2 tyrosines positioned in close proximity to
the CCR5-binding site (Julien et al., 2013; Kwon et al., 2015; Pancera
et al., 2014; Garces et al., 2015; Stewart-Jones et al., 2016). In the pres-
ent study, we utilize sulfated V2mimetic peptides to provide a structur-
al and functional characterization of the sulfotyrosine-mediated
intramolecular interaction between V2 and V3. Moreover, we show
that tyrosine-sulfated V2 mimetic peptides display potent and broad-
spectrum anti-HIV-1 activity, opening new perspectives for the design
of effective HIV-1 entry inhibitors.
2. Materials and methods
2.1. Peptides and proteins
Tyrosine-sulfated and control, non-sulfated mimetic peptides were
produced using solid-phase synthesis technology by American Peptide
Company. Each peptide was puriﬁed to N95% and extensively quality
controlled by HPLC and Mass Spectrometry Electro-Spray. The peptide
aa. sequences were the following: Lys-Val-Gln-Lys-Glu-Tyr(SO3H)-
Ala-Leu-Phe-Tyr(SO3H)-Glu-Leu-Asp-Ile-Val-Pro-Ile-Asp (pV2α-Tys);
Lys-Lys-Gln-Lys-Val-His-Ala-Leu-Phe-Tyr(SO3H)-Lys-Leu-Asp-Ile-Val-
Pro-Ile-Lys (pV2αΕ-Tys); Met-Asp-Tyr-Gln-Val-Ser-Ser-Pro-Ile-
Tyr(SO3H)-Asp-Ile-Asn-Tyr(SO3H)-Tyr-Thr-Ser-Glu-Pro-Ser-Gln-Lys
(pCCR5-Tys); Asp-Pro-Val-Leu-Glu-Phe-Tyr(SO3H)-Lys-Ile-Asp-
Tyr(SO3H)-Ile-Glu-Leu-Ala-Val-Gln-Lys (pSCR-Tys). The peptides were
dissolved in 10 nMNH4OH at 10mg/mL and stored frozen until use. Re-
combinant monomeric gp120 (strain BaL) was obtained from the NIH
AIDS Reagent Program; the recombinant SOSIP trimer (strain BG505)
was produced in 293FS cells and puriﬁed by lectin-afﬁnity and size-ex-
clusion chromatography as described (Julien et al., 2013); 2-domain
sCD4 was obtained from the NIH AIDS Reagent Program; the CD4-
M48U mini-protein (Martin et al., 2003) was a gift of Loic Martin.
2.2. NMR spectroscopy
Peptide pV2α-Tys labeled with 15N was synthesized by American
Peptide Company. All NMR sampleswere prepared by dissolving the ty-
rosine-sulfated pV2α-Tys in aqueous buffer containing 20 mM sodium
phosphate pH 6.8, 50 mM sodium chloride, 0.02% sodium azide and10% deuterium oxide. Binary complexes of either 2-domain sCD4 or re-
combinant gp120 (BaL) with pV2α-Tys and the ternary
sCD4:gp120:pV2α-Tys peptide complex were prepared by combining
all components and incubating on ice for 1 h. The complexes were
then exchanged into NMR buffer and concentrated to a ﬁnal volume
of 200 μL. The ﬁnal concentrations of sCD4, gp120 and pV2α-Tys were
20 μM, 20 μM and 800 μM, respectively. All NMR spectra were collected
at 30 °C on a Bruker DRX 600 MHz NMR spectrometer equipped with a
1H/15N/13C cryoprobe.
Peptide assignments were completed using 2D TOCSY and NOESY
experiments. NOESY spectra were acquired with τmix of 100, 250 and
400 milliseconds (ms). A τmix of 250 ms was found to give optimal
NOE cross peak intensities. To assist in assignment process, we chemi-
cally synthesized pV2α-Tys with 15N–labeled Ala, Ile, Leu, Phe, and Val
at all 8 occurrences of those amino acids. The 15N–labeled pV2α-Tys
peptide, at a concentration of 0.8 mM, was used to collect 2D 1H-15N
heteronuclear single quantum coherence (HSQC), 3D 15N–edited
TOCSY-HSQC and 3D 15N–editedNOESY-HSQC spectra. trNOESY spectra
of pV2α-Tys in the presence of 20 μM sCD4–gp120 were acquired using
the same NOESY pulse scheme and parameters.
NMR structures were computed using the torsion angle dynamics
program Cyana 3.0. NOE assignments were obtained using an iterative
combination of the NOEASSIGN automated peak assignment feature of
Cyana and manual editing. A total of 272 unambiguous, non-redundant
distance constraints were employed in calculation of the ﬁnal ensemble
of 20 structures, which had an average target function of 0.85 ± 0.11
and average RMSD to the mean of 0.41 ± 0.17 Å (backbone) and
1.24 ± 0.21 Å (heavy atoms).
Competition between pCCR5-Tys and pV2α-Tys for binding to the
sCD4:gp120 complex was assessed using 2D NOESY, 2D TOCSY, 2D
HSQC and 3D 15N-edited NOESY-HSQC spectra using 15N–labeled V2
peptide. The sample conditions were the same as described above ex-
cept that the V2 peptide concentration was 0.4 mM. Experimental
data sets were collected with 0, 0.8 mM and 1.6 mM unlabeled
pCCR5-Tys.
2.3. Circular dichroism spectroscopy
Far-UV CD spectra were measured and recorded on a Jasco-810
Spectropolarimeter (Jasco Inc., Easton, MD) equipped with a tempera-
ture controller. Spectra were recorded using a 0.1 cm quartz cuvette,
at 0.3 mg/mL (137 μM), with a scan speed of 50 nm/min, response
time of 1 s, band width of 4 nm and averaging of 5 scans. Peptide con-
centrations were determined spectrophotometrically in 30% acetoni-
trile at 280 nm using a molar extinction coefﬁcient of
2980 M−1 cm−1. The raw CD data were analyzed by Dichroweb and
using the Contin-LL algorithm (http://dichroweb.cryst.bbk.ac.uk/html/
home.shtml), and reference set 3 for secondary structure prediction.
2.4. Surface plasmon resonance
Peptide pV2α-Tys was immobilized on a Biacore CM5 sensor sur-
face. Recombinant gp120 from HIV-1 BaL (at 25-400 nM) or SOSIP tri-
mer (at 12.5–200 nM) were pre-incubated with or without a 2-fold
molar excess of CD4-M48U miniprotein (at 200 nM) for 2 min at
25 μL/min in HBS supplemented with 3 mM EDTA and 0.005% Tween-
20, followed by a 2min dissociation phase on a Biacore 3000 instrument
(GE Healthcare). Surfaces were regenerated after each cycle by a brief
injection of 4.5 M MgCl2.
2.5. Clustal omega alignment
The alignment of V2 domain from6 differentHIV-1 subtypes (A to F)
was performed using all the sequences deposited in the Los Alamos HIV
Sequence Database and selecting one sequence for each patient isolate.
A total of 191 sequences from subtype A, 3306 from subtype B, 2160
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from subtype F were aligned using the Clustal Omega algorithm. Con-
servative substitutions were deﬁned according to the standard Clustal
parameters.
2.6. Secondary structure predictions
Secondary structure predictions were conducted using Agadir (www.
agadir.crg.es/links.jsp), GOR V (www.gor.bb.iastate.edu), Jufo 9 (www.
meilerlab.org/index.php/servers/), Psi Pred (www.bioinf.cs.ucl.ac.uk/
psipred/), andNNPred (www.cmpharm.ucsf.edu/~nomi/nnpredict.html).
2.7. Molecular dynamics simulations
Explicit solvent replica-exchange molecular dynamics (REMD) sim-
ulations were performed on peptide pV2α using the NAMD v.2.8 pro-
gram on the Biowulf Linux cluster at the NIH, Bethesda, MD (http://
biowulf.nih.gov/). The peptide was constructed as a random coil, and
explicitly solvated with TIP3P water molecules and Na+ and Cl− coun-
terions using the VMD program (http://www.ks.uiuc.edu/Research/
vmd/). Periodic boundary conditions were used and electrostatic inter-
actions were calculated using the Particle-Mesh Ewald summation. A
non-bonded term cutoff of 12 Å was used. The CHARMM27 forceﬁeld
was used with CHARMM atom types and charges. Prior to the start of
REMD, the system was minimized using a conjugate gradient method,
followed by slowwarming to 310 K in 10 K increments. Each increment
ran for 5 psec in order to equilibrate the system at a given temperature.
Once the 310 K target temperature was reached, the system was equil-
ibrated for an additional 50 psec at the end of which, a total of 40 rep-
licas were run having a temperature range of 300–600 K for a
cumulative simulation time of 0.6 μsec. Conformations were obtained
at 1 nsec intervals, clustered using an RMS deviation of 5 Å. Representa-
tive structures from the clusters were ranked based on energy and the
structure with the lowest energy was used for further studies.
The FlexPepDock simulation was performed using 2016 independent
trajectories. The pV2a-Tys peptide (residues 168–185) extracted from the
lowest-energy REMD model was oriented to the V3 base by all atom
superposition of Tys173 and Tys177 to Tys100 and Tys100C of mAb
412d in the co-crystal structurewith gp120 (Huang et al., 2007). Trajecto-
ries were analyzed using LigPlot by outputting snapshot structures from
the trajectories at 1 nsec intervals and computing NACCESS-enhanced
LigPlots for each snapshot. The text output was compiled, and the fre-
quencies of observed interactions were used to compare the trajectories.
A single view of the trajectory was computed by averaging the snapshots
using a custom script in VMD. Following averaging, side chains were
reconstructed using the idealize function of Rosetta.
Isothermal-isobaric molecular dynamics simulations of the pV2a-
Tys peptide/gp120 complex were done using a forceﬁeld parameters
for sulfotyrosine obtained by combining CHARMM27 topologies from
related molecules. Isothermal isobaric simulations were conducted as
described for the REMD simulation above with the exception that
once the 310 K target temperature was reached, the system was not
split into replicas. The NAMD default thermostat and barostat was
used. Production data was gathered at 1 nsec intervals. Before
conducting isothermal-isobaric molecular dynamics simulations of the
BG505-SOSIP.664 trimer (PDB ID 4NCO), sulfate groups were added to
Tyr173 and Tyr177 using the SYBYL 7.3 program (Tripos). Forceﬁeld pa-
rameters for sulfotyrosinewere obtained by combining CHARMM27 to-
pologies from related molecules.
2.8. HIV-1 isolates, infection, entry and cell viability assays
Details about the HIV-1 isolates used in this study, the infection
assay in primary human CD4+ T cells, the viral entry assay, and the
cell viability assay have been reported previously (Auerbach et al.,
2012). The HIV-1 entry assay was performed in primary human CD4+T cells using the CCR5-tropic isolate HIV-1 BaL. The cells (106 per repli-
cate; two replicates per treatment) puriﬁed by immunomagnetic beads
and previously activated ex vivowith PHA and IL-2 for 5–7 d were pre-
incubated for 15min at room temperaturewith the inhibitors in 50 μL of
serum-free PBS and then exposed to 500 μL the undiluted viral stocks
for 4 h at 37 °C in the continuous presence of the inhibitors. One aliquot
of untreated cells was incubated for 4 h at 4 °C and served to determine
the background signal level (trypsin-insensitive despite low-tempera-
ture conditions preventing virus entry). After incubation, the cells
were extensively washed with PBS to remove unbound virus and treat-
edwith prewarmed bovine trypsin (Sigma) at 1.25mg/mL for 10min at
37 °C, followed by trypsin inactivation by addition of cold RPMImedium
containing 10% (vol/vol) FBS. The cells were then washed three times
with cold PBS, and theﬁnal dry pelletswere frozen at−80 °C overnight.
The pellets were lysed using 100 μL of 0.5% (wt/vol) Triton X-100, and
the amount of cell-associated p24 protein was quantiﬁed. The speciﬁc
signal was calculated by subtracting from the p24 levels measured in
each test sample the background p24 levelsmeasured in cells incubated
at 4 °C and treated with trypsin.
2.9. CCR5-binding assay
Cf2Th/syn-CCR5 cells (NIH AIDS Reagent Program), which express
high levels of CCR5 on their surface membrane, were used to assess
binding of soluble BG505-SOSIP.664 trimers to CCR5. The cellswere har-
vested at ~80% conﬂuency with enzyme-free cell dissociation buffer
(Gibco). His-tagged BG505-SOSIP.664 trimer and mutants were pre-in-
cubated with or without 2-domain sCD4 for 1 h at 4 °C. After washing
with PBS twice, soluble trimers treatedwith orwithout sCD4were incu-
bated with the cells for 1 h at 4 °C, followed by washing with PBS. PE-
conjugated mouse anti-His tag antibody (Miltenyi Biotec) was added
to the cells for 1-hour at 4 °C. The cells were washed once with PBS,
ﬁxed with 2% PFA and analyzed on a BD FACSCanto. Speciﬁcity of bind-
ing was assessed by abrogation of the signal with an anti-CCR5 mAb
(2D6; Becton Dickinson). Data analysis was performed using the FlowJo
software.
2.10. Soluble CD4-induced HIV-1 envelope-mediated fusion assay
The HIV-1 envelope-mediated fusion assays were performed as pre-
viously described (Salzwedel et al., 2000)with somemodiﬁcation. HeLa
cells infected with recombinant vaccinia viruses expressing HIV-1 BaL
gp160 were used as effectors and Hos-CCR5 cells (CCR5-positive, CD4-
negative) as targets. Soluble CD4was added at 10 μg/mL prior tomixing
effector and target cells.
3. Results
3.1. Direct interaction of a tyrosine-sulfated V2mimetic peptide with HIV-1
gp120
Wepreviously demonstrated that the central region of the V2 loop of
HIV-1 gp120 contains two sulfotyrosines (Tys), at position 173 and 177
(Cimbro et al., 2014). Tys177 is highly conserved across all HIV-1 sub-
types (N99%), whereas Tys173 is conserved in subtypes A, B and C, but
less so in subtypesD, E and Fwith an overall cross-subtype conservation
of ~66% (Fig. S1). To structurally and functionally characterize the sul-
fated region of V2, a 18-mer peptide (pV2α-Tys) spanning aa. 168–
185 from the prototypic CCR5-tropic (R5) isolate BaL, bearing sulfated
tyrosines at both positions 173 and 177, was synthesized and tested
for its ability to interact with full-length recombinant HIV-1 gp120 by
NMR in the presence or absence of sCD4. The 2D nuclear Overhauser ef-
fect (NOE) spectrum (NOESY) of 15N-labeled pV2α-Tys was measured
and comparedwith NOESY spectra acquired in the presence of low con-
centrations of a sCD4:gp120 complex, at a peptide:protein complex
molar ratio of 40:1. Since the rate of NOE buildup is proportional to
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small peptide like pV2α-Tysmay, upon binding to a larger protein com-
plex, become populated with NOE crosspeaks reﬂecting the conforma-
tion of the bound peptide. If the dissociation rate is fast enough to
permit exchange of free and bound peptide molecules during the
NOESY mixing period, intrapeptide NOEs arising while the peptide is
bound will be transferred to the larger population of free peptide
(trNOE). In the absence of the sCD4:gp120 complex, the NOESY spec-
trum was devoid of strong NOE signals (Fig. 1a) suggesting that in the
unbound state pV2α-Tys has an unstructured random coil conforma-
tion. In agreement with this result, circular dichroism (CD) spectral
analysis of the unbound peptide yielded no indications of ordered sec-
ondary structure (Fig. S2). However, addition of the sCD4:gp120 com-
plex had profound effects on the NOESY spectrum, with the
appearance of numerous NOE crosspeaks between pV2α-Tys reso-
nances, consistent with the development of transferred NOEs (trNOE)
reporting on the bound conformation (Fig. 1b). To determine whether
pV2α-Tys binding depends on CD4-induced conformational changes
in gp120, we measured NOESY spectra with either sCD4 or gp120
alone. As expected, no pV2α-Tys trNOEs signals were observed in the
presence of sCD4 alone (Fig. S3). A small number of weak trNOE
crosspeaks were visible when only gp120 was present, but their num-
ber and intensity were dramatically increased when the sCD4:gp120
complex was added. Most of the trNOEs involved the 173–182 segment
(Fig. S4), suggesting that residues in this region are primarily responsi-
ble for interaction with gp120. Comparisons of the trNOEs detected on
the aromatic side chain of Tys177 illustrate the effect of gp120Fig. 1. Nuclear magnetic and surface plasmon resonance analyses of the interaction of a tyrosin
spectrum of a tyrosine-sulfated 18-mer V2mimic, pV2α-Tys, at 0.8 mM. The peptide sequence
the presence of 20 μMCD4:gp120 complex. Monomeric gp120 was derived from the CCR5-trop
to 7.26 ppm in theω2 dimension (Tys177 Hδ). Tys177 NOE signals are shown for pV2α-Tys alo
the cartoons. (d) Surface plasmon resonance (SPR) analysis of the interaction of the tyrosine-su
resonance analysis of the interaction of the tyrosine-sulfated V2 mimic pV2α-Tys with a s
immobilized on the surface of the sensor, while gp120 and the SOSIP trimer were used in the
with a CD4 mimic (CD4-M48U).activation on pV2α-Tys binding and show the prominent role of
Tys177 in stabilizing binding to gp120 (Fig. 1c).
The interaction of pV2α-Tys with gp120 in bothmonomeric and tri-
meric conﬁguration was further investigated by surface plasmon reso-
nance (SPR). The sulfated V2 mimetic peptide was immobilized on the
surface of a CM5 sensor, and either recombinant gp120 (strain BaL) or
a soluble, stabilized gp140 trimer (BG505-SOSIP.664) was injected in
the ﬂuid phase. The tests were performed both in the presence and in
the absence of a functional CD4 mimic (CD4-M48U), which induces
the same gp120 conformational changes as native CD4 (Martin et al.,
2003). Monomeric gp120 bound to the immobilized sulfated peptide
with nanomolar afﬁnity even in the absence of CD4-M48U (ka =
2.39 × 104 1/Ms., kd= 1.89 × 10−3 1/s, KD= 7.91 × 10−8 M); however,
when gp120 was pre-complexed with CD4-M48U, the binding curve
showed a greater magnitude and a faster on-rate despite similar afﬁnity
(ka= 4.83× 104 1/Ms., kd= 3.34× 10−3 1/s, KD=6.91× 10−8M) (Fig.
1d), suggesting that CD4-induced (CD4i) conformational changes in-
crease the number of binding sites for pV2α-Tys. No detectable binding
of gp120, either in the presence or in the absence of CD4-M48U, was re-
corded when the non-sulfated homologous peptide (pV2α) was
immobilized to the sensor (Fig. S5), conﬁrming the critical role of tyro-
sine sulfation in bolstering the interaction with gp120. In contrast to
monomeric gp120, the soluble gp140 trimer was unable to bind to the
sulfated peptide in the absence of the CD4 mimic; however, pre-treat-
mentwith CD4-M48U induced binding of the trimerwith nanomolar af-
ﬁnity (ka = 3.1 × 104 1/Ms, kd = 5.0 × 10−3 1/s, KD = 1.61 × 10−7 M)
(Fig. 1e). These observations are consistent with the native-likee-sulfated V2 mimetic peptide with monomeric and trimeric HIV-1 gp120. (a) 2D NOESY
is indicated at the bottom for reference. (b) 2D trNOESY spectrum of 0.8 mM pV2α-Tys in
ic isolate BaL. (c) 1D slices from the 2D NOESY spectra of 0.8mM pV2α-Tys corresponding
ne (bottom) or in the presence of sCD4, gp120 or the sCD4:gp120 complex as illustrated in
lfated V2mimic pV2α-Tyswithmonomeric HIV-1 gp120 (strain BaL). (e) Surface plasmon
oluble cleaved gp140 trimer (BG505 SOSIP.664). The tyrosine-sulfated V2 mimic was
ﬂow phase at increasing concentrations either in the unliganded form or after treatment
Fig. 2. Competition of a tyrosine-sulfated V2 mimetic peptide with a sulfated CCR5 N-
terminal peptide for gp120 binding. Overlay of 2D trNOESY spectra of 0.4 mM pV2α-Tys
in the presence of 20 μM CD4:gp120 complex before (orange) and after (green)
displacement by a molar excess of a tyrosine-sulfated CCR5 N-terminal peptide, pCCR5-
Tys, at 1.6 mM. The peptide sequence is indicated at the bottom for reference.
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directed against CD4i epitopes (Sanders et al., 2013). Altogether, these
results corroborate the interaction of the sulfated V2 region with the
coreceptor-binding site at the base of the V3 loop, which is partially ac-
cessible in themonomeric formbut inaccessible in the pre-fusion trimer
conformation prior to activation by CD4.
3.2. Competition between tyrosine-sulfated V2 and CCR5 mimetic peptides
for binding to gp120
We previously showed that peptide pV2α-Tys competes with mAb
412d (Cimbro et al., 2014), a tyrosine-sulfated antibody that binds to
the putative CCR5-binding site at the base of the V3 loop (Huang et al.,
2007), suggesting that pV2α-Tys may directly interact with the
coreceptor-binding site. However, it was impossible to exclude that
pV2α-Tys competed with mAb 412d by binding to a different region
of the largemolecular footprint of such antibody. To determinewhether
pV2α-Tys effectively binds to the CCR5-binding site at the base of V3,
we used NMR to investigate the direct competition between pV2α-
Tys and a tyrosine-sulfated peptide derived from the CCR5 N-terminus
(pCCR5-Tys) for gp120 binding. Peptide pCCR5-Tys was added to an
NMR sample containing 15N-labeled pV2α-Tys and the sCD4:gp120
complex. Isotope-edited NOESY spectra showed the disappearance of
the pV2α-Tys trNOEs upon addition of unlabeled pCCR5-Tys, with no
change in the HSQC spectrum (Fig. S6). A similar alteration upon addi-
tion of pCCR5-Tys was seen in the 2D NOESY spectrum (Fig. 2), with
the pV2α-Tys trNOE signals replaced by a new set of peaks that resem-
ble the previously reported trNOE spectrum of a CCR5 peptide bound to
gp120 (Huang et al., 2007). Taken together, these results support the in-
teraction of the tyrosine-sulfated region of V2 with the CCR5 N-termi-
nus-binding site in gp120.
3.3. Structural features of a sulfated V2mimetic peptide interactingwith the
coreceptor-binding site
Previous work demonstrated that a CCR5 N-terminal sulfated pep-
tide adopts a helical conformation upon interaction with gp120
(Huang et al., 2007) with distance constraints derived from trNOE sig-
nals analogous to those observed in this study for the V2-derived
pV2α-Tys in the presence of sCD4:gp120 (Fig. 1d). Although for
pV2α-Tys chemical shift degeneracy precluded the unambiguous as-
signment of medium-range NOEs required for calculation of a high-res-
olution structure, the NMR signals reporting on the gp120-bound
conformation indicated that pV2α-Tys adopts a CCR5-like helical con-
formation upon interaction with the gp120:CD4 complex. Indeed,
NOEs crosspeaks between the Hβ protons of Tys173 and the Hδ protons
of Tys177 (Fig. 3a and b) would only arise if the intervening residues
adopt a helical turn conformation. Sequential NH to NH NOEs (Fig. 3c)
also suggested that gp120-bound pV2α-Tys is in a helical conformation.
An ensemble of structuralmodels obtained from torsion angle dynamics
calculations using the available distance constraints contained a series
of helical turns encompassing the two sulfotyrosines (Fig. 3d), as also il-
lustrated by theNOE distances connecting the side chains of Tys173 and
Tys177 (Fig. 3e). In agreement with the NMR data, both secondary
structure predictions of the entire V2 region (Fig. S7a) and tertiary
structure modeling using a Monte Carlo folding method (ROSETTA)
(Fig. S7b) predicted with high conﬁdence the formation of an α-helix
encompassing the segment between Tys173 and Tys177. To further
evaluate the presence and stability of the α-helix in V2, the conforma-
tional space was exhaustively explored starting from a random-coil
conﬁguration of peptide pV2α-Tys using replica-exchange molecular
dynamics (REMD). Anα-helix was frequently detected among the low-
est-energy conformations (Fig. S7c). The adoption of a helical structure
by the central region of V2 is also supported by the crystal structures of a
V2-derived peptide in complex with mAbs CH58 and CH59, two anti-
bodies derived from subjects enrolled in the RV144 vaccine trial (Liaoet al., 2013), as well as by molecular modeling of an antibody-bound
V2 peptide (Spurrier et al., 2014). Furthermore, a 3/10 helix was recent-
ly observed in the distal part of V2 in recent crystal structures of the
BG505-SOSIP.664 trimer (Kwon et al., 2015; Pancera et al., 2014;
Garces et al., 2015), further supporting the propensity of V2 segments
to adopt a helical fold. Altogether, these ﬁndings corroborate the con-
cept that the highly ﬂexible V2 loop may interchange between alterna-
tive conformations according to its functional state and ligand
interaction.
To further explore the structural features of V2 interaction with the
base of V3, we conducted molecular dynamic (MD) simulations of pep-
tide pV2α-Tys docked onto the structure of CD4-bound gp120, as well
as of the BG505-SOSIP.664 trimer after sulfatemodiﬁcation of the V2 ty-
rosines. The lowest-energy structure of peptide pV2α-Tys identiﬁed by
REMDwas docked onto the structure of a CD4-bound gp120 monomer
(PDB ID: 2QAD) in the same conformation and orientation as those pre-
viously reported for the CCR5 N-terminal peptide (Huang et al., 2007)
(Fig. S8a). Flexible docking by ROSETTA documented an energetically
favorable interaction of pV2α-Tys with the CCR5-binding site at the
base of V3. Analysis by MD conﬁrmed the stability of the complex
throughout a 400 nsec simulation. Insertion of Tys177 into a pocket at
the base of V3 (Fig. S8b), analogous to that occupied by Tys14 of CCR5
Fig. 3.NMR characterization of a tyrosine-sulfated V2mimetic peptide bound to HIV-1 gp120. (a) NOE peaks between the Hb and Hd of Tys173, Phe176 and Tys177 of free pV2a-Tys in a
regionof theNOESY spectrum that corresponds to thedashedbox fromFig. 1D. (b) The same regionof the trNOESY spectrumof pV2a-Tys in the presenceof 20 μMCD4:gp120peaks shows
stronger NOE signals for Tys173, Phe176 and Tys177 side chains include new NOEs (black arrows) linking Hb of Tys173 and Hd of Tys177. (c) Sequential NH to NH NOEs in the trNOESY
spectrum of 0.8 mM pV2a-Tys in the presence of 20 μM CD4:gp120 are consistent with helical conformations. (d) Ensemble of 20 structures of the bound conformation of pV2a-Tys
calculated from trNOE distance constraints. Residues 170–182 are shown for clarity. (e) NOEs connecting the side chains of Tys173 and Tys177 (shown in Fig. 1b) deﬁne a helical turn.
50 R. Cimbro et al. / EBioMedicine 10 (2016) 45–54(Fig. S8a), accounted for 25% of the total binding energy, with a prepon-
derance of electrostatic interactions; in contrast, the binding energy of
non-sulfated Tyr177 was markedly lower (Fig. S8e). The central role of
Tys177 in stabilizing the V2–V3 complex is consistent with very high
conservation of this residue across all HIV-1 subtypes (Fig. S1).
To validate the interaction of the tyrosine-sulfated region of V2 with
the coreceptor-binding site in the context of the full-length HIV-1 enve-
lope trimer, we performed MD simulations with the BG505-SOSIP.664
trimer (PDB ID: 4NCO) after modiﬁcation of the V2 tyrosines to
sulfotyrosines. All the available high-resolution structures of the
BG505-SOSIP.664 trimer (Julien et al., 2013; Kwon et al., 2015;
Pancera et al., 2014; Garces et al., 2015) document an extensive inter-
face between V2 and V3, with Tyr177 directly facing the base of V3 in
a similar orientation as Tys14 of CCR5 and forming an H-bond with
Asn302, a key residue for CCR5 interaction (Fig. S8c). Analysis by MD
after addition of sulfate groups to Tyr173 and Tyr177 did not show
any signiﬁcant alteration in both the local and global conformations of
the V1V2–V3 loop region, with the side chain of Tys177 ﬁtting well
into the sulfotyrosine-binding pocket and establishing additional H-
bonds with Arg298 and Asn300 (Fig. S8d). Taken together, these ﬁnd-
ings support the model of CCR5-like interaction between the tyrosine-
sulfated region of V2 and the base of V3 in the intact trimer structure.
3.4. Inhibition of HIV-1 infection by a tyrosine-sulfated V2 mimetic peptide
Since the NMR data and the predicted model of V2–V3 interaction
documented direct competition between tyrosine-sulfated V2 and
CCR5 mimics for binding to gp120, we investigated whether peptide
pV2α-Tys can interfere with the coreceptor-gp120 interaction andthereby inhibit HIV-1 infection. In acute infection assays performed in
primary human CD4+ T cells, pV2α-Tys potently inhibited infection
by a CCR5-tropic HIV-1 isolate, BaL, in a dose-dependent fashion,
whereas the non-sulfated homologous peptide, pV2α, was ineffective
(Fig. 4a), demonstrating the importance of tyrosine sulfation in bolster-
ing the interaction with gp120. The tyrosine-sulfated CCR5 N-terminal
peptide pCCR5-Tys also showed dose-dependent HIV-1 inhibition,
while its non-sulfated counterpart was ineffective; a tyrosine-sulfated
scrambled peptide with the same aa. content as pV2α-Tys but in ran-
dom sequence (pSCR-Tys), used as a control, did not show signiﬁcant
inhibitory activity (Fig. 4a). Of note, treatment with either pV2α-Tys
or pCCR5-Tys had no detrimental effects on cell viability (Fig. S9).
3.5. HIV-1 inhibition by a sulfated V2mimetic peptide occurs at the level of
viral entry and coreceptor utilization
To deﬁnitively prove that HIV-1 inhibition by pV2α-Tys occurs via
competition with CCR5 coreceptor utilization, we studied the effects of
the peptide on viral entry, CCR5 binding and CCR5-mediated fusion.
Pretreatment with pV2α-Tys effectively inhibited entry of HIV-1 into
primary human CD4+ T cells; the CCR5 N-terminal peptide, pCCR5-
Tys, also reduced viral entry, albeit with lower efﬁciency, while the
non-sulfated counterparts of both peptides were ineffective; a potent
gp41-derived fusion inhibitor used as a control, T20, exerted a potent
inhibitory effect (Fig. 4b). Next, we tested the ability of pV2α-Tys to in-
terfere with binding of the BG505 SOSIP.664 soluble trimer to CCR5
expressed on the surface of a canine thymocytic cell line (CF2). The sol-
uble trimer was pre-activated with sCD4 in order to induce the high-af-
ﬁnity CCR5-binding conformation. Pre-treatment with pV2α-Tys
Fig. 4. Broad-spectrum inhibition of HIV-1 infection, entry and CCR5 utilization by tyrosine-sulfated V2 mimics. (a) Dose-dependent inhibitory effect of the V2 mimic pV2α-Tys and the
CCR5 mimic pCCR5-Tys on cell-free infection of primary human CD4+ T cells by HIV-1, strain BaL; the respective non-sulfated homologous peptides, pV2α and pCCR5, were tested in
parallel, as was a control scrambled sulfated peptide (pSCR-Tys). (b) Effect of pV2α-Tys or pCCR5-Tys (both at 50 μM) on HIV-1 BaL entry into activated primary human CD4+ T cells;
the gp41-derived peptide T20, a pure HIV-1 entry inhibitor, was used as a control at 50 μg/mL. (c) Dose-dependent inhibitory effect of pV2α-Tys or pCCR5-Tys on binding of a soluble
cleaved gp140 trimer (BG505 SOSIP.664) to human CCR5 expressed on the surface of canine thymocytes after pre-activation with sCD4; the scrambled sulfated peptide pSCR-Tys and
an anti-CCR5 mAb (2D6) were used as negative and positive controls, respectively. (d) Effect of pV2α-Tys or pCCR5-Tys (both at 50 μM) on soluble CD4-activated fusion between HIV-
1 BaL envelope-expressing cells and CCR5+ CD4− cells; the entry inhibitor T20 was used as a control at 50 μg/mL. (e) Dominant role of Tys177 in HIV-1 blockade. Dose-dependent
inhibitory effect of peptide pV2α and its modiﬁed versions bearing either double (pV2α-Tys) or single (Tys173 and Tys177) sulfated tyrosines on cell-free infection by HIV-1 BaL in
primary CD4+ T cells. (f) Broad spectrum of HIV-1 inhibition by tyrosine-sulfated V2 mimetic peptides. Peptides pV2α-Tys (clade B), pV2αΕ-Tys (clade E), or pCCR5-Tys (each at
50 μM) were tested on cell-free infection of puriﬁed CD4+ T cells by different strains of HIV-1. Eight primary isolates minimally passaged in vitro (92US714, 92HT599, 07USLR, 07USPC
and 07USSG, subtype B; 97ZA009 and 98IN017, subtype C; 93BR019, subtype F) and 4 laboratory-expanded strains (BaL, JR-FL, ADA, IIIB, all subtype B) were tested. The coreceptor-
usage phenotype of the various HIV-1 isolates is indicated below the strain designations.
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potency similar to that of the sulfated CCR5 N-terminal peptide or an
anti-CCR5 mAb (2D6) used as a control, while the non-sulfated homol-
ogous peptide pV2α and a scrambled sulfated peptide (pSCR-Tys) had
limited effects (Fig. 4c). To further conﬁrm that HIV-1 inhibition by
pV2α-Tys occurs at the level of coreceptor utilization, we used a
sCD4-activated fusion assay that selectively evaluates the effects of in-
hibitors on gp120-CCR5 interaction, downstream of the CD4-binding
step. Both pV2α-Tys and pCCR5-Tys efﬁciently blocked CCR5-mediated
fusion, whereas the non-sulfated homologous peptides had no effects
and the positive control, peptide T20, was highly effective (Fig. 4d).These results conﬁrmed that the sulfated V2 mimic interferes with the
earliest steps of the HIV-1 infectious cycle preventing coreceptor bind-
ing and utilization, a critical step for the progression of the viral entry
process.
3.6. Dominant role of sulfotyrosine 177 in HIV-1 inhibition by V2 mimetic
peptides
To evaluate the relative role of the two V2 sulfotyrosines in the func-
tional interaction with the CCR5-binding site, we tested the HIV-inhibi-
tory activity of peptides bearing sulfate modiﬁcations on individual
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exhibited antiviral activity, Tys177 was more potent than Tys173 (Fig.
4e), suggesting a prominent role of the C-terminal sulfotyrosine,
Tys177 in gp120 interaction; the doubly sulfated peptide remained
the most potent HIV-1 inhibitor, suggesting that tyrosine sulfation at
both positions provides the optimal interactive surface for V2–V3 recog-
nition. These data are consistent with the results of both MD (Fig. S8)
and NMR (Fig. 3), highlighting the key role of the highly conserved
Tys177 in stabilizing the interaction between the central region of V2
and the base of V3.
3.7. Broad-spectrum HIV-1 inhibition by tyrosine-sulfated V2 mimetic
peptides
To assess the breadth of the antiviral activity of pV2α-Tys, we tested
its effects on a panel of 12 HIV-1 strains representative of different
coreceptor-usage phenotypes (6 CCR5-tropic; 6 CXCR4-tropic or dual-
tropic) and genetic subtypes (9 clade B, 2 clade C, 1 clade F), including
8 primary isolates minimally passaged ex vivo; the sulfated CCR5 N-ter-
minal mimic pCCR5-Tys was tested in parallel as a control. Strikingly, all
the HIV-1 isolates testedwere inhibited by pV2α-Tys regardless of their
coreceptor speciﬁcity; in contrast, as previously observed (Cormier et
al., 2000; Cormier et al., 2001; Farzan et al., 2000), the CCR5 N-terminal
peptide showed a restricted activity against CCR5-tropic isolates, but
was inactive against CXCR4-using (R5X4 and X4) isolates (Fig. 4f).
Moreover, we tested a second tyrosine-sulfated peptide derived from
a clade-E HIV-1 envelope (pV2αΕ-Tys), which displays only a single
sulfotyrosine (Tys177) in the central region of V2, with Tyr173
substituted by a histidine, as well as a basic aa. (lysine) at position
178. The clade-E sulfated peptide showed a broad antiviral activity sim-
ilar to that of pV2α-Tys, although 3 HIV-1 strains appeared to be resis-
tant at the peptide concentration utilized; consistent with the
presence of a single sulfotyrosine, pV2αΕ-Tys blockedHIV-1with a gen-
erally lower potency compared to pV2α-Tys (Fig. 4f). Altogether, these
results suggest that the conserved sulfated region of V2 has the ability to
interact with the conserved V3 base of both CCR5- and CXCR4-tropic
HIV-1 isolates, bypassing the structural determinants of coreceptor
speciﬁcity that restrict the activity spectrum of the CCR5 N-terminal
peptide.
4. Discussion
The presence of sulfated tyrosines has been documented in different
ligands of the external HIV-1 envelope glycoprotein, gp120, including
the N-terminal domain of the viral coreceptors (e.g., CCR5) (Farzan et
al., 1999) and the CDRH3 region of antibodies speciﬁc for the
coreceptor-binding site (e.g., 412d) (Choe et al., 2003) and the V1V2 re-
gion (e.g., PG16) (Pejchal et al., 2010); in all of these cases, tyrosine
sulfation was shown to facilitate binding to gp120. The present study
provides another example of tyrosine sulfation relevant to gp120, al-
though the peculiarity of this interaction is that it occurs intramolecu-
larly, locking the central region of V2 onto the coreceptor-binding site
at the V3 base in the unliganded trimer. The V1V2 andV3 loops are ﬂex-
ible and movable structures on the gp120 surface, which in the
unliganded trimer are physically connected at the apex of the envelope
spike, but are rapidly dissociated and dislocated following gp120 activa-
tion by CD4 (Wyatt and Sodroski, 1998). Of note, V2 andV3 are believed
to play a critical role in stabilizing the pre-fusion envelope structure
(Kwon et al., 2012; Sullivan et al., 1993; Xiang et al., 2010), and cooper-
ate in the formation of quaternary epitopes targeted by potent and
broadly neutralizing mAbs (Gorny et al., 2005; Moore et al., 2011;
Walker et al., 2009; Walker et al., 2011). Moreover, the V2 region was
shown to effectively mask neutralization epitopes in V3 (Cao et al.,
1997; Liu et al., 2011; Pinter et al., 2004). Our previouswork document-
ed the presence of sulfated tyrosines in V2 and demonstrated that en-
hancement of V2 sulfation by overexpression of the sulfotransferaseTPST2 reduced HIV-1 sensitivity to neutralization by sCD4 and antibod-
ies to the V3 tip or other CD4i epitopes, while at the same time increas-
ing the sensitivity to trimer-preferring antibodies such as PG9;
conversely, reduction of sulfation by treatment with sodium chlorate
had reciprocal effects (Cimbro et al., 2014). These dichotomous effects
on neutralization sensitivity imply that the V2 sulfotyrosines play a
role in stabilizing the unliganded HIV-1 envelope trimer, shifting the
conformational equilibrium toward amore tightly packed structure. Ac-
cordingly, recent data from our laboratory demonstrate that the V2
sulfotyrosines provide a mechanism of HIV-1 immune evasion from
the bulk of host-produced anti-envelope antibodies (C. Guzzo et al., un-
published data).
The structural and functional features of the tyrosine-sulfated region
of V2 described herein suggest that HIV-1 has modeled this region after
the N-terminal domain of CCR5, exploiting coreceptor mimicry to opti-
mize the intramolecular interaction between V2 and the CCR5-binding
site at the base of the V3 loop. This segment of V2 is inherently ﬂexible
and has been reported to adopt two alternative conformations, α-helix
(Liao et al., 2013) and β-strand (McLellan et al., 2011; Pancera et al.,
2013), when complexed to different antibodies. One possible hypothe-
sis, based on our NMR observations, is that the helical conformation
may be preferentially adopted in the CD4-bound trimer, whose high-
resolution structure has not yet been resolved, whereas a β-strand
may be adopted in the pre-fusion envelope, as observed in the SOSIP tri-
mer structures (Julien et al., 2013; Kwon et al., 2015; Pancera et al.,
2014; Garces et al., 2015; Stewart-Jones et al., 2016). Competition stud-
ies by NMR demonstrated that V2 and CCR5 N-terminal mimics recog-
nize the same region of gp120, in line with our previous
demonstration that a tyrosine-sulfated V2 peptide competes with
mAb 412d, a tyrosine-sulfated antibody speciﬁc for the coreceptor-
binding region (Cimbro et al., 2014). As shown for both CCR5 and
mAb 412d, we found that tyrosine sulfation plays an important role in
bolstering the interaction betweenV2 andV3becausemimetic peptides
lacking sulfation also lacked biological activity. However, both sulfation
and the aromatic ring of the V2 tyrosines appear to play a role in bolster-
ing the V2–V3 interaction. In particular, the aromatic ring of Tys177 ap-
pears to establish important hydrophobic contacts within a deep pocket
at the base of V3, as previously described for Tys14 of CCR5 (Huang et
al., 2007). Since the V2–V3 interaction is a key intramolecular constraint
that holds the envelope trimer in its closed, pre-fusion conformation,
the efﬁciency of gp120 sulfation can signiﬁcantly inﬂuence the general
conformation and stability of the envelope glycoprotein. This has poten-
tial implications both for crystallography studies and in the setting of
vaccine manufacturing, because HIV-1 envelope-based immunogens
are commonly produced in continuous cell lines that are inefﬁcient, at
best, at tyrosine sulfation (Cimbro et al., 2014). Thus, enhancing the
levels of tyrosine sulfation might yield more stable envelope glycopro-
teins more accurately reﬂecting the antigenic make-up of the native
HIV-1 envelope spike.
Our work identiﬁes tyrosine-sulfated V2 mimetic peptides with
potent inhibitory activity on HIV-1 entry and fusion, providing po-
tential leads for the design of therapeutic and vaccine strategies
against HIV-1. It is remarkable that, unlike CCR5 N-terminus pep-
tides, V2 mimetic peptides are active against a broad range of HIV-
1 isolates, irrespective of their coreceptor tropism, highlighting the
overall structural conservation of the coreceptor-binding site in
gp120. The molecular basis for the coreceptor selectivity of CCR5
N-terminal peptides is unclear at present, but it is likely that, besides
the sulfotyrosines, other biochemical or structural features of these
peptides may be incompatible with the binding interface with
CXCR4-tropic gp120. A possible conﬂict site is Asp11 in CCR5,
which may clash with a negative charge at position 440, as frequent-
ly detected in CXCR4-using isolates, while V2 might adapt to both
basic and acidic side-chains at this position because it does not con-
tain charged residues between the two sulfotyrosines. Preliminary
results from our laboratory support this hypothesis.
53R. Cimbro et al. / EBioMedicine 10 (2016) 45–54In summary, our study documents a strategy of microbial mimicry
by a retrovirus with the purpose of occluding a key neutralization target
site and, at the same time, of consolidating the metastable pre-fusion
envelope conformation. Targeting the interface between the sulfated re-
gion of V2 and the base of V3may represent an effective strategy for the
design of effective therapies and vaccines for the control of the HIV-1
pandemic.
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